Study is one of more than 160 abstracts eval­u­ating 10 Celgene com­­pounds across a range of blood cancers

Boudry, Switzerland (Press Release) - Celgene Inter­na­tional Sàrl, a wholly-owned sub­sid­i­ary of Celgene Corpo­ra­tion (NASDAQ:CELG) today announced that data from FIRST^® (Frontline Investigation of Lena­lido­mide + Dexa­meth­a­sone Versus Standard Thalido­mide), its phase III study (MM-020/IFM 07-01) of REV­LI­MID® (lena­lido­mide) in com­bi­na­tion with dex­a­meth­a­sone in patients newly diag­nosed with multiple myeloma (NDMM) in­eli­gible for stem cell trans­plant will be presented on Sunday, Dec. 8 during the plenary session of the 55^thAmerican Society of Hematology annual meeting in New Orleans, La.

Abstracts for the meeting were released today on the society’s Web site at https://ash.confex.com/ash/2013/webprogram/start.html and will be published in the journal Blood. The FIRST study is one of more than 160 abstracts eval­u­ating 10 Celgene com­­pounds across a range of blood cancers.

As reported in the FIRST study abstract, a total of 1,623 patients either ≥65 years of age or not can­di­dates for stem cell trans­plant were ran­dom­ized 1:1:1 into three arms: lena­lido­mide plus low-dose dex­a­meth­a­sone (Rd) in 28-day cycles until disease pro­gres­sion (Arm A); Rd in 28-day cycles for 72 weeks (18 cycles, Arm B); or mel­phalan, pred­ni­sone and thalido­mide in 42-day cycles for 72 weeks (12 cycles, Arm C). Assessments by Inter­na­tional Myeloma Work­ing Group (IMWG) criteria were done after each cycle. Patients with renal im­pair­ment were enrolled, how­ever, patients on dialysis were excluded. Starting doses of lena­lido­mide and dex­a­meth­a­sone were adjusted based on renal function and age, re­spec­tive­ly. Melphalan starting dose was adjusted based on age, absolute neu­tro­phil count, platelet count, and renal function; and thalido­mide was adjusted for age. Dose ad­just­ments were permitted for adverse events. All patients were required to receive anti-thrombotic prophylaxis. Stratification factors in­cluded age, Inter­na­tional Stage System and country.

The pri­mary end­point was a comparison of pro­gres­sion-free survival (PFS) in Arm A vs. Arm C. Secondary end­points in­cluded over­all survival (OS), over­all response rate (ORR), time to response, duration of response (DOR), safety and quality of life (QOL). A preplanned addi­tional analysis in­cluded time from ran­domization to second pro­gres­sion event or death (PFS2). The final preplanned analysis of independently adjudicated progressive disease (PD) events in Arm A vs. Arm C conducted after 960 events of death or PD, and an interim OS analysis in 64% of survival events (574/896 events) were presented in the abstract. Comparisons of PFS and all sec­ond­ary end­points, in­­clud­ing interim OS for all three arms, will be presented at the meeting.

As of the publication of the abstract, 121 patients con­tinue to receive lena­lido­mide on study (Arm A). The median age was 73 (40.0–92.0) years; 35% of patients were aged ≥75 years; and 41% of patients had ISS stage 3 disease.

After a median follow-up of 37 months, the trial met its pri­mary end­point (PFS), demonstrating a 28% reduction in risk of pro­gres­sion or death (HR=0.72; p= 0.00006). The preplanned interim analysis of OS dem­onstrated a 22% reduction in risk of death in favor of Arm A vs. Arm C (HR=0.78, p=0.01685); how­ever, the pre-specified boundary (p<0.0096) was not crossed. All other sec­ond­ary end­points con­sis­tently showed im­prove­ment in favor of Arm A vs. Arm C; ORR (partial response or better) 75% vs. 62% (p < 0.00001), DOR (HR=0.63; p<0.00001), and PFS2 (HR=0.78, p=0.0051).

Relevant Grade 3/4 adverse events in Arm A vs. Arm C were neu­tro­penia (28% vs. 45%), throm­bo­cy­to­penia (8% vs. 11%), febrile neu­tro­penia (1% vs. 3%), in­fec­tion (29% vs. 17%), neu­rop­athy (5% vs.15%), and deep-vein thrombosis (5% vs. 3%). The incidence of sec­ond­ary pri­mary malig­nan­cies (SPM) was eval­u­ated. Hematologic malig­nan­cies were 0.4% in Arm A vs. 2.2% in Arm C; the over­all incidence of solid tumors was identical (2.8%).

REVLIMID^® is not indicated for newly-diagnosed multiple myeloma in any country.

About REVLIMID^®

REVLIMID is approved in com­bi­na­tion with dex­a­meth­a­sone for the treat­ment of patients with multiple myeloma who have received at least one prior ther­apy in nearly 70 countries, encompassing Europe, the Americas, the Middle-East and Asia, and in com­bi­na­tion with dex­a­meth­a­sone for the treat­ment of patients whose disease has progressed after one ther­apy in Australia and New Zealand.

REVLIMID is also approved in the United States, Canada, Switzerland, Australia, New Zealand and several Latin American countries, as well as Malaysia and Israel, for transfusion-dependent anaemia due to low- or intermediate-1-risk MDS asso­ci­ated with a deletion 5q cytogenetic ab­nor­mal­ity with or without addi­tional cytogenetic ab­nor­mal­i­ties and in Europe for the treat­ment of patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelo­dys­plastic syn­dromes asso­ci­ated with an isolated deletion 5q cytogenetic ab­nor­mal­ity when other thera­peutic options are insufficient or inadequate.

In addi­tion, REVLIMID is approved in the United States for the treat­ment of patients with mantle cell lym­phoma (MCL) whose disease has re­lapsed or progressed after two prior ther­a­pies, one of which in­cluded bor­tez­o­mib.

U.S. Regulatory Information for Revlimid

REVLIMID^® (lena­lido­mide) in com­bi­na­tion with dex­a­meth­a­sone is indicated for the treat­ment of patients with multiple myeloma (MM) who have received at least one prior ther­apy

REVLIMID^® (lena­lido­mide) is indicated for the treat­ment of patients with transfusion-dependent anemia due to low- or intermediate-1–risk myelo­dys­plastic syn­dromes (MDS) asso­ci­ated with a deletion 5q cytogenetic ab­nor­mal­ity with or without addi­tional cytogenetic ab­nor­mal­i­ties

REVLIMID^® (lena­lido­mide) is indicated for the treat­ment of patients with mantle cell lym­phoma (MCL) whose disease has re­lapsed or progressed after two prior ther­a­pies, one of which in­cluded bor­tez­o­mib

REVLIMID is not indicated and not recommended for the treat­ment of patients with chronic lym­pho­cytic leukemia (CLL) outside of controlled clin­i­cal trials

Important Safety Information

WARNING: EMBRYO-FETAL TOXICITY, HEMATOLOGIC TOXICITY, and VENOUS THROMBOEMBOLISM

Embryo-Fetal Toxicity

Do not use REVLIMID during pregnancy. Lena­lido­mide, a thalido­mide analogue, caused limb ab­nor­mal­i­ties in a devel­op­mental monkey study. Thalidomide is a known human teratogen that causes severe life-threatening human birth defects. If lena­lido­mide is used during pregnancy, it may cause birth defects or embryo-fetal death. In females of reproductive poten­tial, obtain 2 negative pregnancy tests before starting REVLIMID treat­ment. Females of reproductive poten­tial must use 2 forms of contra­cep­tion or continuously abstain from heterosexual sex during and for 4 weeks after REVLIMID treat­ment. To avoid embryo-fetal exposure to lena­lido­mide, REVLIMID is only avail­able through a restricted distribution pro­gram, the REVLIMID REMS^™ program (formerly known as the “Rev­Assist^®” pro­gram).

Information about the REVLIMID REMS™ Program is avail­able at www.celgeneriskmanagement.com or by calling the manu­­fac­­turer’s toll-free number 1-888-423-5436.

Hematologic Toxicity (Neutropenia and Thrombocytopenia)

REVLIMID can cause sig­nif­i­cant neu­tro­penia and throm­bo­cy­to­penia. Eighty per­cent of patients with del 5q MDS had to have a dose delay/reduction during the major study. Thirty-four per­cent of patients had to have a second dose delay/reduction. Grade 3 or 4 hema­to­logic toxicity was seen in 80% of patients enrolled in the study. Patients on ther­apy for del 5q MDS should have their com­plete blood counts monitored weekly for the first 8 weeks of ther­apy and at least monthly there­after. Patients may require dose inter­rup­tion and/or reduction. Patients may require use of blood prod­uct sup­port and/or growth factors.

Venous Thromboembolism

REVLIMID has dem­onstrated a sig­nif­i­cantly in­­creased risk of deep vein thrombosis (DVT) and pul­mo­nary embolism (PE) in patients with MM who were treated with REVLIMID and dex­a­meth­a­sone ther­apy. Patients and physicians are advised to be observant for the signs and symp­toms of thromboembolism. Patients should be instructed to seek medical care if they develop symp­toms such as shortness of breath, chest pain, or arm or leg swelling. It is not known whether pro­phy­lactic anticoagulation or antiplatelet ther­apy prescribed in conjunction with REVLIMID may lessen the poten­tial for venous thromboembolism. The de­ci­sion to take pro­phy­lactic measures should be done carefully after an assess­ment of an individual patient’s under­lying risk factors.

CONTRAINDICATIONS

Pregnancy:

• REVLIMID can cause fetal harm when administered to a pregnant female. Lenalidomide is contraindicated in females who are pregnant. If this drug is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus

Allergic Reactions:

• REVLIMID is contraindicated in patients who have demonstrated hypersensitivity (e.g., angioedema, Stevens-Johnson syndrome, toxic epidermal necrolysis) to lenalidomide

WARNINGS AND PRECAUTIONS

Embryo-Fetal Toxicity:

• REVLIMID is an analogue of thalidomide, a known human teratogen that causes life-threatening human birth defects or embryo-fetal death. An embryo-fetal development study in monkeys indicates that lenalidomide produced malformations in the offspring of female monkeys who received the drug during pregnancy, similar to birth defects observed in humans following exposure to thalidomide during pregnancy
• Females of Reproductive Potential: Must avoid pregnancy for at least 4 weeks before beginning REVLIMID therapy, during therapy, during dose interruptions and for at least 4 weeks after completing therapy. Must commit either to abstain continuously from heterosexual sexual intercourse or to use two methods of reliable birth control beginning 4 weeks prior to initiating treatment with REVLIMID, during therapy, during dose interruptions and continuing for 4 weeks following dis­con­tin­u­a­tion of REVLIMID therapy. Must obtain 2 negative pregnancy tests prior to initiating therapy
• Males: Lenalidomide is present in the semen of patients receiving the drug. Males must always use a latex or synthetic condom during any sexual contact with females of reproductive potential while taking REVLIMID and for up to 28 days after discontinuing REVLIMID, even if they have undergone a successful vasectomy. Male patients taking REVLIMID must not donate sperm
• Blood Donation: Patients must not donate blood during treatment with REVLIMID and for 1 month following dis­con­tin­u­a­tion of the drug because the blood might be given to a pregnant female patient whose fetus must not be exposed to REVLIMID

REVLIMID REMS Program

Because of embryo-fetal risk, REVLIMID is avail­able only through a restricted pro­gram under a Risk Eval­u­a­tion and Mitigation Strategy (REMS) the REVLIMID REMS Program (formerly known as the “RevAssist^®” Program). Prescribers and pharmacies must be certified with the pro­gram and patients must sign an agree­ment form and comply with the require­ments. Further in­­for­ma­tion about the REVLIMID REMS program is avail­able at www.celgeneriskmanagement.com or by telephone at 1-888-423-5436

Hematologic Toxicity: REVLIMID can cause sig­nif­i­cant neu­tro­penia and throm­bo­cy­to­penia. MM: Patients taking REVLIMID for MM should have their com­plete blood counts monitored every 2 weeks for the first 12 weeks and then monthly there­after. In the pooled MM trials Grade 3 and 4 hema­to­logic toxicities were more frequent in patients treated with the com­bi­na­tion of REVLIMID and dex­a­meth­a­sone than in patients treated with dex­a­meth­a­sone alone. MCL: Patients taking REVLIMID for MCL should have their com­plete blood counts monitored weekly for the first cycle (28 days), every 2 weeks during cycles 2-4, and then monthly there­after. In the MCL trial, Grade 3 or 4 neu­tro­penia was reported in 43% of the patients. Grade 3 or 4 throm­bo­cy­to­penia was reported in 28% of the patients. Patients may require dose inter­rup­tion and/or dose reduction

Venous Thromboembolism: Venous thrombo­embolic events (predominantly deep venous thrombosis and pul­mo­nary embolism) have occurred in patients with MM treated with lena­lido­mide com­bi­na­tion ther­apy and patients with MDS or MCL treated with lena­lido­mide mono­therapy. It is not known whether pro­phy­lactic anticoagulation or antiplatelet ther­apy prescribed in conjunction with REVLIMID may lessen the poten­tial for venous thromboembolism

Increased Mortality in Patients With CLL: In a clin­i­cal trial in the first line treat­ment of patients with CLL, single agent REVLIMID ther­apy in­­creased the risk of death by 92%. Serious adverse cardiovascular reac­tions, in­­clud­ing atrial fibrillation, myo­cardial infarction, and cardiac failure occurred more frequently in the REVLIMID treat­ment arm. REVLIMID is not indicated and not recommended for use in CLL outside of controlled clin­i­cal trials

Second Primary Malignancies: Patients with MM treated with lena­lido­mide in studies in­­clud­ing mel­phalan and stem cell trans­plan­ta­tion had a higher incidence of second pri­mary malig­nan­cies, particularly acute mye­log­e­nous leukemia (AML) and Hodgkin lym­phoma, compared to patients in the control arms who received similar ther­apy but did not receive lena­lido­mide. Monitor patients for the devel­op­ment of second malig­nan­cies. Take into account both the poten­tial benefit of lena­lido­mide and the risk of second pri­mary malig­nan­cies when con­sidering treat­ment with lena­lido­mide

Hepatotoxicity: Hepatic failure, in­­clud­ing fatal cases, has occurred in patients treated with lena­lido­mide in com­bi­na­tion with dex­a­meth­a­sone. The mech­a­nism of drug-induced hepato­tox­ic­ity is unknown. Pre-existing viral liver disease, elevated base­line liver enzymes, and concomitant medications may be risk factors. Monitor liver enzymes periodically. Stop REVLIMID upon elevation of liver enzymes. After return to base­line values, treat­ment at a lower dose may be con­sidered

Allergic Reactions: Angioedema and serious dermatologic reac­tions in­­clud­ing Stevens-Johnson syn­drome (SJS) and toxic epider­mal necrolysis (TEN) have been reported. These events can be fatal. Patients with a prior history of Grade 4 rash asso­ci­ated with thalido­mide treat­ment should not receive REVLIMID. REVLIMID inter­rup­tion or dis­con­tin­u­a­tion should be con­sidered for Grade 2-3 skin rash. REVLIMID must be dis­con­tinued for angioedema, Grade 4 rash, exfoliative or bullous rash, or if SJS or TEN is sus­pected and should not be resumed fol­low­ing dis­con­tin­u­a­tion for these reac­tions. REVLIMID capsules con­tain lactose. Risk-benefit of REVLIMID treat­ment should be eval­u­ated in patients with lactose intolerance

Tumor Lysis Syndrome: Fatal instances of tumor lysis syn­drome (TLS) have been reported during treat­ment with lena­lido­mide. The patients at risk of TLS are those with high tumor burden prior to treat­ment. These patients should be monitored closely and appro­pri­ate precautions taken

Tumor Flare Reaction: Tumor flare reac­tion (TFR) has occurred during inves­ti­ga­tional use of lena­lido­mide for CLL and lym­phoma, and is char­ac­ter­ized by tender lymph node swelling, low grade fever, pain and rash. REVLIMID is not indicated and not recommended for use in CLL outside of controlled clin­i­cal trials

Monitoring and evaluation for TFR is recommended in patients with MCL. Tumor flare may mimic the pro­gres­sion of disease (PD). In patients with Grade 3 or 4 TFR, it is recommended to withhold treat­ment with lena­lido­mide until TFR resolves to ≤ Grade 1. In the MCL trial, approx­i­mately 10% of subjects ex­peri­enced TFR; all reports were Grade 1 or 2 in severity. All of the events occurred in cycle 1 and one patient developed TFR again in cycle 11. Lena­lido­mide may be con­tinued in patients with Grade 1 and 2 TFR without inter­rup­tion or modification, at the physician’s discretion. Patients with Grade 1 or 2 TFR may also be treated with corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs) and/or narcotic analgesics for man­agement of TFR symp­toms. Patients with Grade 3 or 4 TFR may be treated for man­agement of symp­toms per the guidance for treat­ment of Grade 1 and 2 TFR

ADVERSE REACTIONS

Multiple Myeloma

• In the REVLIMID/​dex­a­meth­a­sone treatment group, 269 patients (76%) underwent at least one dose interruption with or without a dose reduction of REVLIMID compared to 199 patients (57%) in the placebo/​dex­a­meth­a­sone treatment group
• Of these patients who had one dose interruption with or without a dose reduction, 76% (269/353) vs 57% (199/350), 50% in the REVLIMID/​dex­a­meth­a­sone treatment group underwent at least one additional dose interruption with or without a dose reduction compared to 21% in the placebo/​dex­a­meth­a­sone treatment group
• Most adverse events and Grade 3/4 adverse events were more frequent in MM patients who received the combination of REVLIMID/dex­a­meth­a­sone compared to placebo/​dex­a­meth­a­sone
• Grade 3/4 neu­tro­penia occurred in 33.4% vs 3.4%; 2.3% experienced Grade 3/4 febrile neu­tro­penia vs 0%
• Deep vein thrombosis (DVT) was reported as a serious adverse drug reaction (7.4%) or Grade 3/4 (8.2%) compared to 3.1% and 3.4%. Discontinuations due to DVT were reported at comparable rates between groups
• Pulmonary embolism (PE) was reported as a serious adverse drug reaction (3.7%) or Grade 3/4 (4.0%) compared to 0.9% and 0.9%. Discontinuations due to PE were reported at comparable rates between groups
• Adverse reactions reported in ≥15% of MM patients (REVLIMID/​dex­a­meth­a­sone vs dex­a­meth­a­sone/placebo): fatigue (44% vs 42%), neu­tro­penia (42% vs 6%), constipation (41% vs 21%), diarrhea (39% vs 27%), muscle cramp (33% vs 21%), anemia (31% vs 24%), pyrexia (28% vs 23%), peripheral edema (26% vs 21%), nausea (26% vs 21%), back pain (26% vs 19%), upper respiratory tract infection (25% vs 16%), dyspnea (24% vs 17%), dizziness (23% vs 17%), throm­bo­cy­to­penia (22% vs 11%), rash (21% vs 9%), tremor (21% vs 7%), weight decreased (20% vs 15%), nasopharyngitis (18% vs 9%), blurred vision (17% vs 11%), anorexia (16% vs 10%), and dysgeusia (15% vs 10%)

Myelodysplastic Syndromes

• Thrombocytopenia (61.5%; 91/148) and neu­tro­penia (58.8%; 87/148) were the most frequently reported adverse events observed in the del 5q MDS population
• Grade 3 and 4 adverse events reported in ≥ 5% of patients with del 5q MDS were neu­tro­penia (53%), throm­bo­cy­to­penia (50%), pneumonia (7%), rash (7%), anemia (6%), leukopenia (5%), fatigue (5%), dyspnea (5%), and back pain (5%)
• Other adverse events reported in ≥15% of del 5q MDS patients (REVLIMID): diarrhea (49%), pruritus (42%), rash (36%), fatigue (31%), constipation (24%), nausea (24%), naso­pharyn­gitis (23%), arthralgia (22%), pyrexia (21%), back pain (21%), peripheral edema (20%), cough (20%), dizziness (20%), headache (20%), muscle cramp (18%), dyspnea (17%), pharyngitis (16%), epistaxis (15%), asthenia (15%), upper respiratory tract infection (15%)

Mantle Cell Lymphoma

• Grade 3 and 4 adverse events reported in ≥5% of patients treated with REVLIMID in the MCL trial (N=134) included neu­tro­penia (43%), throm­bo­cy­to­penia (28%), anemia (11%), pneumonia (9%), leukopenia (7%), fatigue (7%), diarrhea (6%), dyspnea (6%), and febrile neu­tro­penia (6%)
• Serious adverse events reported in ≥2 patients treated with REVLIMID mono­ther­a­py for MCL included chronic obstructive pulmonary disease, clostridium difficile colitis, sepsis, basal cell carcinoma, and supra­ven­tricu­lar tachy­cardia
• Adverse events reported in ≥15% of patients treated with REVLIMID in the MCL trial included neu­tro­penia (49%), throm­bo­cy­to­penia (36%), fatigue (34%), anemia (31%), diarrhea (31%), nausea (30%), cough (28%), pyrexia (23%), rash (22%), dyspnea (18%), pruritus (17%), peripheral edema (16%), con­sti­pa­tion (16%), and leukopenia (15%)
• Adverse events occurring in patients treated with REVLIMID in the MCL trial resulted in at least one dose interruption in 76 (57%) patients, at least one dose reduction in 51 (38%) patients, and dis­con­tin­u­a­tion of treatment in 26 (19%) patients

DRUG INTERACTIONS

Periodic monitoring of digoxin plasma levels, in accordance with clin­i­cal judgment and based on standard clin­i­cal practice in patients receiving this medication, is recommended during admin­istra­tion of REVLIMID. It is not known whether there is an inter­action be­tween dex­a­meth­a­sone and warfarin. Close monitoring of PT and INR is recommended in MM patients taking concomitant warfarin. Erythropoietic agents, or other agents, that may in­­crease the risk of thrombosis, such as estrogen con­taining ther­a­pies, should be used with caution in MM patients receiving lena­lido­mide with dex­a­meth­a­sone

USE IN SPECIFIC POPULATIONS

Pregnancy: If pregnancy does occur during treat­ment, im­medi­ately dis­con­tinue the drug. Under these con­di­tions, refer patient to an obstetrician/gynecologist ex­peri­enced in reproductive toxicity for further evaluation and counseling. Any sus­pected fetal exposure to REVLIMID must be reported to the FDA via the MedWatch pro­gram at 1-800-332-1088 and also to Celgene Corpo­ra­tion at 1-888-423-5436

Nursing Mothers: It is not known whether REVLIMID is excreted in human milk. Because many drugs are excreted in human milk and because of the poten­tial for adverse reac­tions in nursing infants, a de­ci­sion should be made whether to dis­con­tinue nursing or the drug, taking into account the importance of the drug to the mother

Pediatric Use: Safety and effectiveness in pediatric patients below the age of 18 have not been estab­lish­ed

Geriatric Use: Since elderly patients are more likely to have de­creased renal function, care should be taken in dose selection. Monitor renal function

Renal Impairment: Since REVLIMID is primarily excreted unchanged by the kidney, ad­just­ments to the starting dose of REVLIMID are recommended to provide appro­pri­ate drug exposure in patients with mod­er­ate (CLcr 30-60 mL/min) or severe renal im­pair­ment (CLcr < 30 mL/min) and in patients on dialysis

Please see full Prescribing Information, in­­clud­ing Boxed WARNINGS, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS, and ADVERSE REACTIONS.

About Celgene

Celgene Inter­na­tional Sàrl, located in Boudry, in the Canton of Neuchâtel, Switzerland, is a wholly-owned sub­sid­i­ary and inter­na­tional headquarters of Celgene Corpo­ra­tion. Celgene Corpo­ra­tion, headquartered in Summit, New Jersey, is an integrated global pharma­ceu­tical com­pany engaged primarily in the discovery, devel­op­ment and com­mer­cial­iza­tion of inno­va­tive ther­a­pies for the treat­ment of cancer and inflammatory diseases through gene and protein reg­u­la­tion. For more in­­for­ma­tion, please visit www.celgene.com.

Forward-Looking Statements

This press release con­tains forward-looking state­ments, which are generally state­ments that are not historical facts. Forward-looking state­ments can be identified by the words "expects," "antic­i­pates," "believes," "intends," "estimates," "plans," "will," “outlook” and similar ex­pres­sions. Forward-looking state­ments are based on man­agement’s current plans, esti­mates, assump­tions and projections, and speak only as of the date they are made. We under­take no obli­ga­tion to update any forward-looking state­ment in light of new in­­for­ma­tion or future events, except as other­wise required by law. Forward-looking state­ments involve in­her­ent risks and un­cer­tain­ties, most of which are dif­fi­cult to predict and are generally beyond our control. Actual results or out­comes may differ ma­teri­ally from those implied by the forward-looking state­ments as a result of the impact of a number of factors, many of which are discussed in more detail in Celgene Corpo­ra­tion’s Annual Report on Form 10-K and other reports filed with the Securities and Exchange Com­mis­sion.

Source: Celgene.